Regel Therapeutics details its proprietary T3 platform and d

/PRNewswire/ -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene...

Related Keywords

Berkeley , California , United States , Cambridge , Cambridgeshire , United Kingdom , San Francisco , Wendy Chung , Orrin Devinsky , Steve Ruchefsky , Andrew Schiermeier , Nadav Ahituv , Kevin Bender , Gord Fishell , University Of California , Broad Institute , Department Of Neurology , Harvard Medical School , Epilepsy Center , Therapeutic Technology , Institute Member Of The Broad , Regel Co , Institute For Human Genetics , Therapeutic Sciences , Regel Therapeutics Inc , Clinical Genetics At Columbia University , Scientific Advisory Board , Regel Co Founder Orrin Devinsky , Scientific Advisory , Targeted Therapeutic Technology , Cougar Biotechnology , Regel President , Avencell Therapeutics , Founder Orrin Devinsky , Kennedy Family Professor , Clinical Genetics , Columbia University , Human Genetics , Institute Member , Associate Professor , Computer Amp Electronics , Health Care Amp Hospitals , Medical Pharmaceuticals , Biotechnology , Pharmaceuticals , Personnel Announcements , New Products Amp Services ,